Introduction
Drug resistance is a major obstacle in the management of cancer using chemotherapy. Multidrug resistance (MDR) describes the ability of cancer cells to develop resistance to a broad range of structurally and functionally distinct chemotherapeutic agents [1] . Many tumor cells become resistant to commonly used cytotoxic drugs because of the overexpression of ATP-binding cassette (ABC) transporters [2, 3] , such as the inducible P-glycoprotein (Pgp) gene known as a drug efflux transporter. One common approach to overcoming MDR is a co-delivery strategy that involves using a small interference RNA (siRNA) to silence Pgp expression and an appropriate anticancer drug for targeting cancer cells. Multidrug resistance-associated protein 1 (MRP1) is a peculiar member of the ABC transporter superfamily that is capable of transporting a wide variety of neutral hydrophobic compounds, such as Pgp [4] . Although Pgp has been thoroughly described in the literatures, much less is known about the recently identified MRP1. Additionally, unlike Pgp, no clinically useful high-specificity inhibitors for MRP1 have been developed [2, 5] . Despite the importance of MRP1 in MDR cancer cells, the study of MRP1 is severely limited.
Metastatic prostate cancer is one of the most therapy-resistant human neoplasms because of its resistance to a broad range of antineoplastic agents, making it the second leading cause of cancer-related deaths in men worldwide [6, 7] . MRP1 gene expression is the predominant mechanism of acquired MDR in prostate cancer [8] [9] [10] [11] [12] . Effectively blocking the pump action of MRP1 results in the intracellular accumulation of drugs, thereby increasing cells sensitive to cytotoxic drugs [13] . However, the transcription of MRP1 has been found to be (FBS), and trypsin-2.5% (w/v) EDTA solution were purchased from Gibco. BD Matrigel Basement Membrane Matrix was purchased from BD Biosciences.
Characterization
The morphologies of MSNs, and Dox@MSN-Dz were imaged using transmission electron microscopy (TEM; Hitachi, H-7650), operated at an acceleration voltage of 80 kV. Steady-state absorption spectra were acquired using a DU800 UV spectrometer (Beckman). Fluorescence intensity spectra were acquired using a Cary Eclipse Fluorescence spectrometer (Varian). A ZetaSizer Nano was used to measure the surface charges of the MSNs samples in a pH 7.4 solution. Zeta potential distributions were obtained by averaging 10 measurements. The samples were prepared at a concentration of 2 mg in 1 ml of deionized water (ddH 2 O). Before each measurement, each sample was sonicated for 1 min to preclude aggregation.
Preparation of Dox@MSN
Dox@MSN samples were prepared and characterized as previously described [56] . In brief, CTAB was dissolved in aqueous NH 3 , then added to TEOS by stirring for 5 h and aged at 40°C for 24 h. Solid samples were collected by centrifuging, washing, and redispersing the precipitate with ddH 2 O and ethanol several times. Surfactant templates were extracted from acidic ethanol heated to 65°C over a period of 24 h. The pH-sensitive linker was conjugated onto the MSN nanochannels surface through hydrazone bonds, and another set of hydrazide groups was introduced to covalently react with the ketone groups of Dox. Because pH-sensitive linker hydrazone bond hydrolyzes in the acidic environment of endosomes and lysosomes, Dox could be intracellularly released from the MSN nanochannels. The loading percentage of Dox within MSNs was 0.71% (wt %) and determined by measuring changes in the optical absorption of the solution phase at 490 nm. A concentration of 100 μg ml −1 of Dox@MSN contains an equivalent Dox dose of 0.7 μg ml −1 (which is in accordance with the loading percentage, 0.7%). Dz targeting the G 1311 U junction in the human c-Jun mRNA [33] was synthesizance against nuclease degradation, the phosphorothioate modifications were incorporated in the first and last two phosphodiester linkages [37, 38] . The total number w for green fluorescence detection. The scrambled control (Scr), which has the same length and net charge as Dz and retains an intact catalytic domain, but differs from its hybridizing arms, was used as a negative control. The sequences were the following: Dz: 5′-cgggaggaAGGCTAGCTACAACGAGaggcgttg-3′FlTC; Scr: 5′-gcgacgtg AGGCTAGCTACAACGAGtggaggag3′FlTC.
Preparation of Dox@MSN-Dz
The surface of Dox@MSN was modified by the positive charge of TA (quaternary ammonium type) and the zeta potential was +24.4 mV. The Dox@MSN-Dz was form mainly by an electrostatic interaction between negatively charged phosphate groups of Dz and positively charged groups of TA on the Dox@MSN surface. A different amount of Dz was added to a fixed concentration of the MSNs or Dox@MSN in pH4 ddH 2 O, shaken for 2 h at room temperature in total darkness, and the samples were centrifuged. The amount of Dz bound was determined according to the amount of Dz unbound in the supernatant, which was measured using UV-vis spectroscopy at 260 nm subtracted from the total amount added. The optimal binding of particles and Dz was prepared by using 100 μg ml −1 of MSNs or Dox@MSN, and 1.6 μM of Dz in a total volume of 100 μl of pH4 ddH 2 O. To assess the binding of the Dz to the particle surface, the absorbance of MSNs, free Dox, MSN-Dz, Dox@MSN, and Dox@MSN-Dz were measured at 260 nm with particles resuspended in pH4 ddH 2 O; and the fluorescence intensities of free Dz, free Dox, Dox@MSN, and Dox@MSN-Dz were measured using a fluorescence spectrometer. The samples were excited at 488 nm with the fluorescence at 520 nm for 3′-FITC of Dz and 590 nm for Dox, respectively.
In vitro release study To characterize the release of Dz and Dox from MSNs, 4 mg ml −1 of Dox@MSN-Dz was incubated in 5.5 and 7.4 pH PBS at 37°C, in total darkness. The released amounts of Dz were measured using UV-vis spectroscopy at 260 nm and the released amounts of Dox were measured using an optical emission spectrometer (excited at 488 nm and fluoresced at 590 nm). Release media were removed for analysis at specific time intervals by centrifuging at 12 000 rpm for 20 min and placing solid residues into identical volumes of PBS buffer solution for subsequent analysis. The released percentage of Dz and Dox in the solution phase was determined by measuring the concentration.
Cell culture and transfection PC-3 (a metastatic human prostate carcinoma cell line) cells were obtained from Bioresource Collection and research Center (BCRC; Food Industry Research and Development Institute, Taiwan). The cells were maintained in F-12K medium with 10% FBS and were passaged at 70%-80% confluency every 2-4 days. All cells were in a humidified incubator at 37°C and a 5% CO 2 atmosphere. Adherent cells were detached through incubation with trypsin-EDTA. For transfections, the PC-3 cells were treated with Lipofectamine 2000 (Invitrogen) with or without Dz and Scr in the presence of a serum-free medium. The cells were collected and assayed at various times after transfection.
Visualizing the intracellular uptake and localization using confocal microscopy To visualize the intracellular uptake and localization of Dox@MSN-Dz in PC-3 cells, 4×10 4 PC-3 cells were seeded onto eight-well chamber slides and incubated overnight in 5% CO 2 at 37°C. The cells were treated with 100 μg ml −1 of Dox@MSN-Dz in a serum-free medium for 24 h at 37°C in total darkness, respectively.
Subsequently, the cells were washed with PBS and then a fresh culture medium was added to the cells, which were incubated for another 24 h at 37°C. Finally, the cells were washed twice with PBS and stained with Hoechst 33 342 and 1 m mol l −1 of LysoTracker Red DND-99 (Molecular Probes L-7528) for nuclei, endosomes and lysosomes for approximately 5 min in 5% CO 2 at 37°C and the cells were transferred to a serum-free medium.
Images of the cells were taken on a LEICA TCS SPE confocal imaging system with fluorescence observed at excitation wavelengths of 350, 488, 577, 590, and 647 nm.
Colony formation assay for cell survival To implement the chemotherapeutic efficacy of Dox@MSN-Dz in PC-3 cells, cell survival was determined by performing a colony formation assay [65, 67] . Briefly, PC-3 c 100 μg ml −1 of MSNs, 100 μg ml −1 of Dox@MSN, 100 μg ml −1 of Dox@MSN-Dz, 100 μg ml −1 of Dox@MSN-Scr, and 100 μg ml −1 of MSN-Dz in 24-well plates were incubated for 24 h in 5% CO 2 at 37°C, respectively. Then, 5.2×10 2 cells were resuspended in medium containing 10% FBS in six-well plates (Corning, New York). The cells were incubated for 10 days in 5% CO 2 at 37°C. Then, cells were subsequently fixed with 4% PFA for 30 min and stained with 2% crystal violet for 6 min at room temperature. Finally, more than 50 cell numbers of colonies were counted and each experiment performed at least 3 times.
Western blot for detected of protein expression
To verify that Dz influences on the protein expression of c-Jun and downregulation of MRP1 expression, the PC-3 cells were untreated as control group and treated with 100 μg ml −1 of MSNs, 100 μg ml −1 of Dox@MSN, 100 μg ml −1 of Dox@MSN-Dz, 100 μg ml −1 of Dox@MSN-Scr, transfected with 1.6 μM of Dz (equivalent to the amount of Dz electrostatic interaction on the surface of Dox@MSN), and 0.7 μg ml −1 of free Dox (equivalent to the amount of Dox in the inner MSNs) for 48 h. The proteins were then transferred onto polyvinylidene difluoride (PVDF) membranes. The nonspecific binding of the membranes was blocked using 5% nonfat dry milk in Tris-buffered saline (TBS) and 0.5% (v/v) Tween-20 (TBS-T) for 1 h. The membranes were washed with TBS-T 3 times and incubated with specific primary antibodies. The antibodies employed against c-Jun 1: 200 (orb14436, Biorbyt), MRP1 1:500 (GTX116046, GeneTex), and Profilin1 1:2000 (GTX102072, GeneTex) in 5% nonfat dry milk in TBS-T shaken overnight at 4°C. Subsequently, the membranes were washed with TBS-T and incubated with a secondary antibody (horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit IgG) for 1 h at room temperature. After washing the membrane three times with TBS-T, the band was revealed by enhanced chemiluminescence system using ECL western blotting detection reagents, followed by exposure to an autoradiographic film. To ensure equal protein loading, the blot was probed with antibodies to Profilin1 as an internal control. Protein levels were quantified using densitometry. Protein bands were corrected for Profilin1 and results are expressed relative to untreated cells. Relative protein levels were quantified using Image J software (NIH). 100 μg ml −1 of Dox@MSN, 100 μg ml −1 of Dox@MSN-Dz, 100 μg ml −1 of Dox@MSN-Scr and 0.7 μg ml
of free Dox in a serum-free medium then incubated for 24 h in 5% CO 2 at 37°C, in total darkness, respectively. After the incubation, the cells wers subsequently added to the cells, which were incubated for another 24 h at 37°C. Finally, the cells were collected and resuspended in 1 ml of PBS, after which they were analyzed by using an FACS Calibur flow cytometer (BD Biosciences) with an excitation wavelength of 488 nm and emission wavelength of 585 nm. The cell counts were 10 000.
Matrigel invasion assay for observing cell invasion
To assess Dox@MSN-Dz inhibition the invasion capacity, PC-3 cells were untreated as control group and treated with 100 μg ml −1 of MSNs, 100 μg ml −1 of Dox@MSN, 100 μg ml −1 of Dox@MSN-Dz, 100 μg ml −1 of Dox@MSN-Scr, transfected with 1.6 μM of Dz, transfected with 1.6 μM of Scr, and 0.7 μg ml −1 of free Dox for 24 h and incubated overnight in 5% CO 2 at 37°C. After 24 h, the cells were detached using trypsin-EDTA and resuspended in a serum-free medium. The PC-3 cells invasion through matrigel-coated filters was measured by using a BD Biocoat Matrigel Invasion Chamber (24-well, 8 μm pore size). Matrigel (BD Biosciences 356237) was diluted to 30 μg in a cold F-12K medium in each well and applied to the top side of polyethylene terephthalate (PET) track-etched membranes with a pore size of 8 μm, coating for 1.5 h at room temperature. A medium containing 10% FBS was added to the lower chamber as a chemoattractant and the cells were seeded on the upper chamber at a density of 6×10 4 cells/well in 200 μl of serum-free medium. The invasion chambers were incubated in 5% CO 2 at 37°C for 24 h. After incubation, the cells in the upper surface of the membrane were removed using a cotton swab and then fixed the cells which already invaded across the matrigel to the lower surface of the membrane. Cells fixed with 4% PFA for 10 min and stained with H&E at room temperature. To quantify invasive cells, pictures of the cells were taken from randomly chosen fields using a light microscope and counted by Image J software (version 1.37c, NIH). Each experiment was conducted in triplicate.
Wound-healing assay for detecting cell migration
To determine the role of Dox@MSN-Dz in PC-3 cellular migration in vitro, PC-3 cells (4×10 4 cells/well) were seeded in a Culture-Insert (ibidi, 80209) and a confluent layer was produced within 24 h. Cells were untreated as control group and treated with 100 μg ml −1 of MSNs, 100 μg ml −1 of Dox@MSN, 100 μg ml −1 of Dox@MSN-Dz, 100 μg ml −1 of Dox@MSN-Scr, and transfected with 1.6 μM of Dz for 24 h. The Cuture-Insert was subsequently removed, the dish was filled with a fresh serum-containing medium and then cells incubated for another 24 h in 5% CO 2 at 37°C. The cellular debris was then washed with PBS. The wound closure was monitored and photographed at 0 and 24 h by using phase-contrast microscopy. The width of the cell-free gap was 500 μm±50 μm. To quantify cell migration, pictures of the initial wounded monolayers were compared with the corresponding pictures of cells at the end of the incubation. Artificial lines fitting the cutting edges were drawn on pictures of the original wounds and overlaid on the pictures of cultures after incubation. Pictures of the cells were taken from randomly chosen fields using a light microscope and counted by using Image J software (version 1.37c, NIH).
Results and discussion
Characterization of Dox@MSN-Dz The synthesis and characterization of the conjugation of Dox to MSNs' nanochannel walls by pH-sensitive linkers has been described elsewhere [56, 57] . In this study, the loading fraction of Dox within MSNs was determined by measuring the changes in the optical absorption of Dox at 490 nm. The Dox@MSN loading content (0.7 wt %) was the same as that in our previous study [57] . Subsequently, the outermost surfaces of MSNs were modified with trimethylammonium (TA) groups, which increased the nanoparticle surface charge (zeta potential was +24.4 mV). After the addition of Dz to the Dox@MSN solution, the surface charge changed to +4.26 mV, indicating that Dz strongly attached to the TA-functionalized Dox@MSN through charge interactions. The scrambled Dz sequence (Scr) replaced Dz as the negative control for Dox@MSN-Scr synthesis thereafter. The TEM image of MSNs ( figure 1(A) ) showed the well-ordered porous structure as hexagonal shapes, with an average particle size of approximately 55±5.7 nm. The morphology of Dz functionalized Dox@MSN was presented in figure 1(B) , indicating that the surface coating of Dz covered the porous structure of MSNs. Photographs of the centrifuged MSNs and Dox@MSN (figures 1(C) and (D)) showed white and red pellets, respectively, indicating that Dox was within MSNs. Additionally, when FITC-labeled Dz was adsorbed on the surface of Dox@MSN, the centrifuged Dox@MSN-Dz ( figure 1(E) ) or Dox@MSN-Scr ( figure 1(F) ) showed yellow pellets. The anticancer drug loading and surface modification were further verified by emission spectroscopy analysis (figure 2). It is clear that the characteristic bands at 520 and 590 nm correspond to the emission of the dye FITC and Dox, respectively. The MSNs did not show any prominent emission peaks. In addition, compared with free Dox (figure 2, blue line), no obvious emission change was observed for Dox@MSN ( figure 2, red line) . Dox@MSN-Dz (figure 2, green line) exhibited similar emission profile mixing with free Dz (figure 2, purple line) and Dox at 520 and 590 nm, respectively, providing the evidence of Dox and Dz linked with MSNs.
The pH-sensitive drug release profile of Dox@MSN through the hydrazone bond was demonstrated in our previous study [56] . In this work, however, the release profile of Dox@MSN-Dz obtained by simultaneously monitoring the emission of the released Dox and Dz was indistinguishable because Dox is itself weakly fluorescent and highly interfered by the strong fluorophore of FITC from Dz. Consequently, the release of Dox@MSN-Dz properties in a time-dependent manner used Dz without FITC labeling. The released amounts of Dz were determined by observing the optical absorbance of the supernatant at 260 nm, whereas Dox release was quantified by its characteristic emission at 590 nm. Figure 3 reveals that both the cumulative release profiles of Dz and Dox were time-and pH-dependent. Although the release rates of Dz were faster at pH of 7.4 than at a pH of 5.5, endocytosis has been known to take less than 4 h [59] [60] [61] [62] [63] . Approximately 20% of Dox ( figure 3(B) , red line) was cleaved from the MSNs' nanochannels at a pH value of 5.5 within 48 h, suggesting that Dox was continuously released from MSNs in acidic endosome and lysosome environments. Surprisingly, over 50% of Dz ( figure 3(A) , green line) was released within 16 h under the same conditions (pH 5.5), indicating that Dz was released much faster from the MSNs' surface than Dox was from MSNs' nanochannels. This could be due to some reasons such as the localization in MSNs and the binding force with MSNs. It is noted that the determination of Dz release was interfered by Dox after 16 h and thus the characteristic absorbance at 260 nm was indistinguishable. Interestingly, the release profiles of Dox have significant difference between Dox@MSN and Dox@MSN-Dz. This could be attributed mainly to the surface Dz blocking the release of Dox, leading to the delayed release of Dox in Dox@MSN-Dz. These results strongly suggest that most amount of Dz releases faster than Dox in acidic environments and then Dz takes time to inhibit drug efflux transporter before Dox release.
To verify that Dox@MSN-Dz could enter the cells through endocytosis and accumulate within endosomes and lysosomes, confocal fluorescence microscopy was used to visualize the intracellular uptake and localization of Dox@MSN-Dz (figure 4). After adding Dox@MSN-Dz to the PC-3 cells, the cell nucleus and lysosomes were labeled with the blue fluorescence of Hoechst 33342 and the red fluorescence of lysotracker, respectively. After 24 h of incubation, the green fluorescence (3′-FITC of Dz) of Dox@MSN-Dz was readily apparent within PC-3 cells and co-localized with the lysotracker red fluorescence (the merged image at 24 h in figure 4 ). This indicates that Dox@MSN-Dz carried Dz into PC-3 cells and that Dox@MSN-Dz had become highly concentrated within endosomes and lysosomes at 24 h. Additionally, in a subsequent confocal study, we observed that the released Dz from Dox@MSN-Dz could escape from the endosomes and lysosomes to the perinuclear region (the merged image at 48 h in figure 4) . It is noted that Dox@MSN-Dz with low Dox loading content (0.7 wt%) and thus the MSNs release of Dox in cells was difficult to observe by confocal microscopy (data not shown).
DOX@MSN-Dz enhances cellular retention of doxorubicin in PC-3 Cells
To assess the efficacy of Dz delivered by Dox@MSN-Dz in PC-3 cells, the c-Jun expression was followed by western blot ( figure 5(A) ). Protein levels were also quantified by densitometry as shown in the bottom panel of figure 5(A) . This demonstrated a 60% or 70% reduction in c-Jun expression in cells treated with Dox@MSN-Dz and those transfected with Dz using lipofectamine, respectively. No obvious c-Jun protein down-regulation was observed in cells treated with MSNs, Dox@MSN, and free Dox, implying that neither MSNs nor Dox can efficiently regulate c-Jun protein expression. As mentioned, Dox@MSN-Scr was used as a negative control to rule out any impact by the Dz delivery. Therefore, the ability of Dox@MSN-Dz to downregulate c-Jun protein expression is comparable to that by Dz transfection, providing indirect evidence of Dz release from MSNs and its escape from endosomes and lysosomes.
It has been known that cells transfected with mutant c-Jun can downregulate MRP1 expression [64] . In this work, to verify the the MRP-1 expression be down-regulated after knockdown of the c-Jun protein expression by Dz, the MRP1 expression was further determined by western blot ( figure 5(B) ). The ratio of MRP1 to Profilin1 was expressed relative to the untreated control group and the protein levels were quantified using densitometry ( figure 5(B) bottom panel) . PC-3 cells treated with Dox@MSN-Dz showed significant abrogation of MRP1 expression with protein levels similar to that of the control group. Additionally, cells treated with free Dox and Dox@MSN both up-regulated the MRP1 protein expression approximately 2-fold compared with the control group, indicating that Dox upregulated MRP1 expression in Dox-resistant PC-3 cells. This is consistent with previous observations in the literatures; an increase in MRP family expression accompanying the acquisition of drug resistance has been observed in prostate cancer [12] and human small cell lung cancer (SCLC) cells [65, 66] . The proposed mechanism involves the activated form of c-Jun binding to the AP-1 site in the MRP1 promoter. Drug induced MRP1 expression could be abrogated by transfecting a dominant-negative c-Jun plasmid in leukemic cells [64] and pretreating a c-Jun N-terminal kinase (JNK) inhibitor in SCLC cells [65] . All these observations indicate the crucial contribution of c-Jun in the modulation of MRP1 protein expression. Therefore, our co-delivery strategy of Dox@MSN-Dz could provide Dz to downregulate c-Jun protein expression, block the recruitment of c-Jun in the MRP1 promoter and subsequently inhibit Dox to upregulate the transcription of MRP1.
Another, concern was whether the intracellular retention of Dox was enhanced by blocking the transcription of MRP1. The intracellular Dox concentration can be determined by measuring cellular Dox fluorescence intensity in flow cytometry systems ( figure 5(C) ). Noteworthy, the comparatively low Dox uptake after treatment with free Dox was improved by delivering Dox@MSN, which was demonstrated in MES-SA/Dx-5 with drug efflux transporters of Pgp in our previous study [57] . This mechanism was speculated to alter drug delivery pathways through endocytosis and thus bypass the Pgp efflux pump to antagonize Pgp-mediated MDR. In this work, the intracellular Dox concentration increased significantly in cells treated with Dox@MSN-Dz ( figure 5(C) , green line) compared with those treated with free Dox ( figure 5(C) , red line), Dox@MSN ( figure 5(C), pink line) , and Dox@MSN-Scr ( figure 5(C), yellow line) . These results suggested that although Dox@MSN can take more Dox into cells, some released Dox might be rapidly exported from the cell before reaching the nucleus. Therefore, knockdown of c-Jun protein expression facilitates the MRP1 down-regulation and thus allows more Dox being slowly released from MSNs to enter the nucleus where it induces cytotoxicity.
Dox@MSN-Dz enhances the efficacy of chemotherapy
To evaluate the chemotherapeutic efficacy of Dox@MSN-Dz, the colony formation assay was employed to determine the effect. [65, 67] . Photographs of colonies in figure 6 showed the remarkable reduction in cell survival by treatment of Dox@MSN-Dz more than other control groups. Additionally, the statistical evaluation of the bottom panel in figure 6 showed a significantly enhanced cell-killing effect of Dox@MSN-Dz toward PC-3 cells with over 80% reduction of surviving fraction; in comparison, PC-3 cells treated with Dox@MSN still had a 60% survival comparable to those treated with MSN-Dz. This result suggests an additive effect from Dox and Dz that are being delivered by Dox@MSN-Dz. It should be noted that the duration of time it takes for Dz to exert its effect, thereby the Dox sensitivity will not be fully restored. Chemotherapeutics generally show a delicate balance between maintaining a sufficiently high dose to kill cancer cells, and avoiding a dose so high that it causes toxicity and side effects [68] . Our Dox and Dz co-delivery system enhanced cell death that is very attractive because of the low drug dose and high therapeutic efficacy. Among the groups, free Dox with 0.7 μg ml −1
, the equivalent Dox concentration in Dox@MSN-Dz, was not effective to suppress the PC-3 cells because of its low concentration (data not shown). This result was consistent with our previous study in which 0.5 μg ml −1 free Dox imposed no significant cytotoxicity in MTT assay to drug resistant cells [57] .
DOX@MSN-Dz reduces the invasiveness and migration of PC-3 cells
Metastasis is the cumulative result of multiple changes in tumor cells and their microenvironment that enables cells to migrate or invade into healthy host tissue, and subsequently establishes a secondary tumor [69] . It was found that the transcription factor c-Jun activity is related to cell invasion and migration capacity [19-22, 24-26, 70-72] , playing an essential role in metastasis of cancer cells. However, down-regulation the expression of c-Jun by Dz has been reported that significantly reduced the formation of metastases [44, [73] [74] [75] [76] . In this study, to verify the capability of Dox@MSN-Dz to inhibit cellular invasion, an in vitro c-Jun can reduce the potentially invasive phenotype of cells after cells transfected with Dz rather than with Scr. However, Dox@MSN-Dz presented the most significant reduction of invasion compared with other groups, suggesting that the co-delivery system for invasion inhibition in PC-3 cells yielded a more significant decrement of invasion than treatment with Dox@MSN or Dz. Notably, Dox provided significant reductions in invasion of approximately 30% and 50% in cells treated with Dox@MSN and free Dox, respectively. This indicated that Dox-induced cytotoxicity led to cell death and then resulted in decrement of invasion, which is similar to the observation reported by Doillon et al [77] .
To determine the role of Dox@MSN-Dz in cell migration, the monolayers of PC-3 cells were treated with MSNs, Dox@MSN, Dox@MSN-Dz, Dox@MSN-Scr, and transfected with Dz in a wound-healing assay for 24 h, then incubated for another 24 h after removing the insert. The wound closure was monitored and photographed at 0 and 24 h by phase-contrast microscopy and all images were used to quantify the number of cells that had migrated into the denuded (i.e., wounded) zone. the total release of Dox is comparable to 0.7 μg ml −1 when cells treated with 100 μg ml −1 of Dox@MSN or Dox@MSN-Dz. However, Harisi et al determined that the migration was preferentially affected upon applying Dox concentration at least 1 μg ml −1 in PC-3 cell cultures [78] . Consequently, Dox from Dox@MSN-Dz showed an additive reduction of cell invasion, but a negligible contribution to cell migration. In previous reports, the co-delivery of genetic and chemotherapeutic drugs has been widely investigated for the effective treatment of various cancers [46, [79] [80] [81] [82] [83] . However, most of them treated or released gene and chemotherapeutic drugs simultaneously without controlling the release of substances in the proper order or at the proper time. In our study, a multifunctional platform of MSNs possessing topologically distinct domains was used by sequentially conjugating Dox into the MSNs' nanochannels for chemotherapy and adsorbing Dz onto the MSNs' outermost surface to target c-Jun for gene therapy. Such a design resulted in the release order from Dz to Dox, thereby Dz taking times to exert its effect before Dox functioning. Additionally, the continuous release of Dox can be proceeding in acidic environments via the pH-sensitive linker. Consequently, Dox delivered by Dox@MSN-Dz significantly enhances the intracellular Dox concentration more than free Dox and Dox@MSN in the absence of Dz co-delivery. Meng et al also used the key features of the interior and exterior design modification in their PEI-coated MSNs for the co-delivery of Dox and siRNA, demonstrating the restoration of Dox sensitivity for the induction of apoptosis and cytotoxicity through the knockdown of Pgp gene expression [53, 54] . Unlikely, our Dox@MSN-Dz system provides a proof-of-principle study to simultaneously improve cytotoxic killing and inhibit metastasis through the regulation of c-Jun by Dz.
It is imperative to briefly mention the importance of selecting Dz instead of siRNA. Naked RNA molecules are labile in acidic environments, such as in late endosomes and lysosomes, where they can be destroyed by enzymatic degradation. Therefore, it is generally accepted that encapsulation formulation is necessary for siRNA delivery [32] . To simplify our nanoparticle design, Dz modified with protection groups can be easily used to bind to the outermost surface of MSNs through electrostatic interaction.
Our work demonstrated the feasibility of the Dox@MSN-Dz system not only improving the cytotoxicity of Dox by downregulating the drug efflux transporter of MRP-1, but also inhibiting cell migration and invasion through the regulation of c-Jun. Dass et al demonstrated the impressive in vivo efficacy of the co-treatment of chitosan-encapsulated Dz13 plus Dox for regressing the growth and metastasis of pre-established tumors [75] . Very recently, the same group used a chitosan-encapsulated Dox and Dz13 (DDNPs) to control osteosarcoma progression, resulting in the inhibition of tumor growth and reducing the incidence of metastasis to the lungs in animal experiments [83] . Their study proved that the co-treatment or co-delivery strategy for Dox and Dz are both effective in vivo. Therefore, it is reasonable to expect that our Dox@MSN-Dz has the potential to be further used in in vivo applications.
Conclusion
The co-delivery of genetic and chemotherapeutic drugs has been widely investigated for the effective treatment of various cancers in an additive or synergistic fashion. We demonstrated the use of MSNs in sequentially conjugating Dox into the nanochannels of MSNs for chemotherapy and Dz onto the outermost surface of MSNs to target c-Jun for gene therapy. Such a design not only allowed the release order of Dz then Dox, but also provided the continuous release of Dox through the pH-sensitive linker in acidic environments. In Doxresistant PC-3 cells, Dox delivered using the Dox@MSN-Dz system significantly enhanced the intracellular Dox concentration more than free Dox and Dox@MSN did in the absence of a Dz co-delivery, and significantly improved cytotoxic killing, which was evaluated using a colony formation assay. Additionally, the significant reductions of invasiveness and migration related to metastasis were also observed in cells treated using Dox@MSN-Dz. Therefore, our results contribute new insight into the treatment of malignant cancers, indicating that studying its potential for development in clinical translation is worthwhile.
